There is a high degree of variation in patient response to medicines. The McLeod laboratory uses genetic tools to perform in vitro, ex vivo, and clinical evaluations to discover, validate, and apply molecular predictors of therapeutic outcome. This includes candidate-gene and genome-wide human association studies, computational and functional characterization of newly discovered genetic variants, and the use of multiple strains of inbred mice to provide a broadbased approach toward understanding inherited sources of variability in drug effects.

Selected publications:

Yen JL, McLeod HL. (2007) Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. Mar 9; [Epub ahead of print]

Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. (2007) Genetic Variation in the B-Type Natiuretic Peptide Pathway Affects BNP Levels.
Cardiovasc Drugs Ther. Mar 3; [Epub ahead of print]

Marsh S, McLeod HL. (2007) Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother. 8:119-27.

Marsh S, Van Booven DJ, McLeod HL. (2006) Global pharmacogenetics: giving the genome to the masses.  Pharmacogenomics 7(4):625-31.

Marsh S, McLeod HL. (2006) Pharmacogenomics: from bedside to clinical practice.  Hum Mol Genet. 15 Spec No 1:R89-93.

Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL. (2006) Expression of drug pathway proteins is independent of tumour type.  J Pathol. Jun;209(2):213-9.

Grice GR, Seaton TL, Woodland AM, McLeod HL. (2006) Defining the opportunity for pharmacogenetic intervention in primary care.  Pharmacogenomics 7(1):61-5.

Marsh S, Mallon MA, Goodfellow P, McLeod HL. (2005) Concordance of pharmacogenetic markers in germline and colorectal tumor DNA.  Pharmacogenomics 6(8):873-7.

Freimuth RR, Xiao M, Marsh S, Minton M, Addleman N, Van Booven DJ, McLeod HL, Kwok PY. (2005) Polymorphism discovery in 51 chemotherapy pathway genes.  Hum Mol Genet. 14(23):3595-603.